North Carolina Headlines

DelveInsight’s report, “Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Traumatic Brain Injury landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Traumatic Brain Injury market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Traumatic Brain Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Traumatic Brain Injury Market Forecast

Some of the key facts of the Traumatic Brain Injury Market Report:

• The Traumatic Brain Injury market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In June 2026, Alpha Cognition has been granted a U.S. patent for ALPHA-1062, a novel therapeutic candidate being developed for traumatic brain injury (TBI). The patented therapy is designed to address neuronal damage and cognitive dysfunction associated with TBI and has the potential to become a first-in-class treatment in this area. Preclinical studies have demonstrated promising neuroprotective activity, including the ability to reduce pathological tau accumulation, a key factor linked to long-term neurological impairment and cognitive decline following brain injury. These findings highlight ALPHA-1062’s potential to improve outcomes for patients suffering from TBI-related complications.

• In May 2026, Oragenics advanced its Phase IIa clinical program for ONP-002 by opening a second study site in Australia. The trial is evaluating ONP-002, an investigational intranasal neurosteroid therapy being developed for the treatment of concussion and mild traumatic brain injury (mTBI). The expansion is expected to support patient recruitment and accelerate the clinical assessment of this promising candidate in addressing the significant unmet needs associated with brain injuries.

• In March 2026, Oragenics, Inc. has obtained important regulatory clearance in Australia to begin a Phase IIa clinical trial evaluating ONP-002, a novel therapy being developed for Concussion and Mild Traumatic Brain Injury (mTBI), after receiving final approval from the Human Research Ethics Committee (HREC).

• In December 2025, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR; OTCQB: BETRF; FRA: NPAU), an emerging biotechnology firm, is advancing the development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide (LSD). The Company announced that the final IND-enabling studies for BETR-001 are underway, with plans to submit the IND and initiate human clinical trials in the second half of 2026. The initial development focus includes treating Traumatic Brain Injury (TBI), cluster headaches, and migraine. BETR-001 may also hold promise for a wider spectrum of psychiatric conditions, which the company intends to investigate as development progresses.

• In October 2025, SanBio announced a partial amendment to the marketing authorization for AKUUGO and submitted a revision of its approval conditions to the MHLW. The proposal, filed in June 2025, was accepted, and formal approval of the partial change by the MHLW is anticipated. Following the NHI price listing, the company plans to launch AKUUGO suspension for intracranial implantation.

• In July 2025, Oxeia Biopharmaceuticals announced plans to secure additional funding to initiate their Phase IIb clinical trial. Facing limited interest from traditional investors, the company has partnered with StartEngine, a leading crowdfunding platform. Results from the pilot Phase IIa trial of OXE103 demonstrated promising potential as a treatment for concussion, and the company remains optimistic about advancing to the next Phase IIb study.

• In 2024, the total TBI market across the 7MM was approximately USD 1,300 million and is projected to grow by 2034.

• In 2024, the United States dominated the 7MM market, accounting for 85% of the total, followed by Japan, which is expected to experience growth over the forecast period from 2025 to 2034.

• In 2024, within the EU4 and the UK, Germany accounted for approximately 29% of the total market, followed by France with 22% in the 7MM.

• In 2024, the United States recorded the highest number of incident traumatic brain injury (TBI) cases in the 7MM, totaling approximately 3,042,000 cases.

• Within the EU4 and the UK, Germany reported the highest number of cases, followed by France, while Spain recorded the lowest number of cases.

• In 2024, around 125,000 adults and 49,000 children in the United Kingdom were affected by traumatic brain injury (TBI).

• In 2024, Japan reported approximately 280,000 mild TBI cases, around 43,500 moderate TBI cases, and roughly 5,900 severe TBI cases.

• In 2024, males were the most affected group by TBI across the 7MM, with higher incidence and impact compared to females.

• Key Traumatic Brain Injury Companies: SanBio, Oxeia Biopharmaceuticals, Oragenics, Hope Biosciences, SHINKEI Therapeutics, VeriNOS Pharmaceuticals GmbH, Cellvation, Inc., Abalonex, LLC, The SanBio Group, Hope Biosciences, CereMark Pharma, LLC, Hamad Medical Corporation, Supernus Pharmaceuticals, Inc., Merz Pharmaceuticals GmbH, and others

• Key Traumatic Brain Injury Therapies: AKUUGO (Vandefitemcel), OXE103, ONP-002, HB-adMSCs, MR-301, Ronopterin (VAS203), CEVA101, ABX-101, SB623 (vandefitemcel), Autologous HB-adMSCs, [F-18]Flornaptitril, ABX-101, Propranolol, MYOBLOC, NT 201, and others

• The Traumatic Brain Injury market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Traumatic Brain Injury pipeline products will significantly revolutionize the Traumatic Brain Injury market dynamics.

• According to DelveInsight’s analysis, the total number of incident cases of Traumatic Brain Injury (TBI) in the 7MM was approximately 4,254 thousand in 2023 and is expected to increase at a significant compound annual growth rate (CAGR) throughout the forecast period from 2024 to 2034.

• Among the EU4 and UK countries, Germany reported the highest number of incident cases of Traumatic Brain Injury (TBI) in 2023, with 238 thousand cases, while Spain had the lowest at 134 thousand cases. The number of cases is anticipated to increase in the EU4 and the UK.

• The estimates indicate that the incident population of Traumatic Brain Injury (TBI) in Japan is projected to be 325 thousand cases in 2023, but this number is expected to decline by 2034.

• In 2023, 66% of males and 34% of females in the 7MM experienced Traumatic Brain Injury (TBI). These cases are expected to increase during the forecast period from 2024 to 2034.

Traumatic Brain Injury Overview

Traumatic Brain Injury (TBI) is a serious injury to the brain caused by an external force, such as a blow or jolt to the head, a fall, or an accident. TBIs can range from mild concussions to severe brain damage, leading to various physical, cognitive, and emotional symptoms. Common symptoms include headaches, confusion, dizziness, memory problems, and difficulty concentrating. Treatment may involve medication, rehabilitation, and supportive care, depending on the severity of the injury. Early diagnosis and intervention are crucial for improving outcomes and minimizing long-term effects.

Get a Free sample for the Traumatic Brain Injury Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/traumatic-brain-injury-market

Traumatic Brain Injury Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Traumatic Brain Injury Epidemiology Segmentation:

The Traumatic Brain Injury market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Traumatic Brain Injury

• Prevalent Cases of Traumatic Brain Injury by severity

• Gender-specific Prevalence of Traumatic Brain Injury

• Diagnosed Cases of Episodic and Chronic Traumatic Brain Injury

Download the report to understand which factors are driving Traumatic Brain Injury epidemiology trends @ Traumatic Brain Injury Epidemiology Forecast

Traumatic Brain Injury Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Traumatic Brain Injury market or expected to get launched during the study period. The analysis covers Traumatic Brain Injury market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Traumatic Brain Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Traumatic Brain Injury Therapies and Key Companies

• AKUUGO (Vandefitemcel): SanBio

• OXE103: Oxeia Biopharmaceuticals

• ONP-002: Oragenics

• HB-adMSCs: Hope Biosciences

• MR-301: SHINKEI Therapeutics

• Ronopterin (VAS203): VeriNOS Pharmaceuticals GmbH

• CEVA101: Cellvation, Inc.

• ABX-101: Abalonex, LLC

• SB623 (vandefitemcel): The SanBio Group

• Autologous HB-adMSCs: Hope Biosciences

• [F-18]Flornaptitril: CereMark Pharma, LLC

• ABX-101: Abalonex, LLC

• Propranolol: Hamad Medical Corporation

• MYOBLOC: Supernus Pharmaceuticals, Inc.

• NT 201: Merz Pharmaceuticals GmbH

Discover more about therapies set to grab major Traumatic Brain Injury market share @ Traumatic Brain Injury Treatment Landscape

Traumatic Brain Injury Market Drivers

• Increasing incidence of traumatic brain injuries resulting from road accidents, falls, sports-related injuries, and military combat exposure is expanding the patient population.

• Growing awareness of TBI diagnosis and management is leading to higher detection rates and greater demand for effective treatment options.

• Advancements in neuroimaging and diagnostic technologies are enabling earlier and more accurate identification of brain injuries.

• Rising investments in neuroprotection and regenerative medicine research are accelerating the development of innovative TBI therapies.

• Expanding clinical pipeline of novel therapeutics, including stem cell therapies, neuroprotective agents, and anti-inflammatory treatments, is creating growth opportunities.

Traumatic Brain Injury Market Barriers

• Lack of FDA-approved disease-modifying therapies remains a significant challenge, with most current treatments focused on symptom management and supportive care.

• Complex pathophysiology of TBI makes drug development difficult, contributing to high clinical trial failure rates.

• Variability in injury severity and patient response complicates clinical study design and treatment standardization.

• Limited understanding of long-term neurological consequences can hinder the development of targeted therapies.

• High costs associated with advanced diagnostics, treatment, and rehabilitation services may restrict patient access

Scope of the Traumatic Brain Injury Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Traumatic Brain Injury Companies: SanBio, Oxeia Biopharmaceuticals, Oragenics, Hope Biosciences, SHINKEI Therapeutics, VeriNOS Pharmaceuticals GmbH, Cellvation, Inc., Abalonex, LLC, The SanBio Group, Hope Biosciences, CereMark Pharma, LLC, Hamad Medical Corporation, Supernus Pharmaceuticals, Inc., Merz Pharmaceuticals GmbH, and others

• Key Traumatic Brain Injury Therapies: AKUUGO (Vandefitemcel), OXE103, ONP-002, HB-adMSCs, MR-301, Ronopterin (VAS203), CEVA101, ABX-101, SB623 (vandefitemcel), Autologous HB-adMSCs, [F-18]Flornaptitril, ABX-101, Propranolol, MYOBLOC, NT 201, and others

• Traumatic Brain Injury Therapeutic Assessment: Traumatic Brain Injury current marketed and Traumatic Brain Injury emerging therapies

• Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury market drivers and Traumatic Brain Injury market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Traumatic Brain Injury Unmet Needs, KOL’s views, Analyst’s views, Traumatic Brain Injury Market Access and Reimbursement

To know more about Traumatic Brain Injury companies working in the treatment market, visit @ Traumatic Brain Injury Clinical Trials and Therapeutic Assessment

Table of Contents

1. Traumatic Brain Injury Market Report Introduction

2. Executive Summary for Traumatic Brain Injury

3. SWOT analysis of Traumatic Brain Injury

4. Traumatic Brain Injury Patient Share (%) Overview at a Glance

5. Traumatic Brain Injury Market Overview at a Glance

6. Traumatic Brain Injury Disease Background and Overview

7. Traumatic Brain Injury Epidemiology and Patient Population

8. Country-Specific Patient Population of Traumatic Brain Injury

9. Traumatic Brain Injury Current Treatment and Medical Practices

10. Traumatic Brain Injury Unmet Needs

11. Traumatic Brain Injury Emerging Therapies

12. Traumatic Brain Injury Market Outlook

13. Country-Wise Traumatic Brain Injury Market Analysis (2020–2034)

14. Traumatic Brain Injury Market Access and Reimbursement of Therapies

15. Traumatic Brain Injury Market Drivers

16. Traumatic Brain Injury Market Barriers

17. Traumatic Brain Injury Appendix

18. Traumatic Brain Injury Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679 Source: https://www.delveinsight.com/report-store.php
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/